Purchase Order 36C24226P0556
Award Date 4/15/26
Potential Completion Date 4/21/26
Potential Value $39K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs, Veterans Integrated Service Network 2 (VISN 2) awarded a firm fixed-price purchase order to Theracom, L.L.C. for TAKHZYRO 150MG/ML injection in 2ML syringe formulation on February 24, 2026. The contract has a ceiling value of $38,875.02 with an ultimate completion date of March 24, 2026. The award was made without a set-aside designation, reflecting full and open competition. Theracom, a Kentucky-based pharmaceutical specialty distributor headquartered in...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5) awarded a firm fixed-price purchase order to Theracom, L.L.C. for $38,097.52 for the supply of TAKHZYRO 150 MG, a specialized biologic pharmaceutical therapy. The contract was awarded on March 2, 2026, with an ultimate completion date of March 4, 2026, and no set-aside designation was utilized. Theracom, headquartered in Shepherdsville, Kentucky and operating from its Brooks, Kentucky facility, is a specialized...
- Theracom, L.L.C., a child entity, has been awarded a firm fixed price purchase order by the Veterans Integrated Service Network 2 (VISN 2), a civilian component of the Department of Veterans Affairs, for the supply of TAKHZYRO 150MG. The contract, issued on December 1, 2025, carries a ceiling value of $75,478.12 and is scheduled for ultimate completion by December 30, 2025. The contract was awarded without a set-aside designation and will be performed in Brooks, Kentucky. TAKHZYRO...
- This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 awards Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price contract to supply TAKHZYRO 150MG/ML SYRINGE 2ML PER SYRINGE with a quantity of 2. The contract is issued against Takeda Pharmaceuticals America Inc.'s existing Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB), with performance taking place in Lexington, Massachusetts. No...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- The Defense Logistics Agency awarded a $34,342.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Takhzyro 300 mg/2 ml syringes on April 25, 2025, with completion required by May 16, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively granted with no set-aside designation, and...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order against the company's GSA Schedule contract for Pharmaceuticals and Drugs. The delivery order is for TAKHZYRO 150MG/ML SYRINGE 2ML SYRINGE (2) to be supplied to Veterans Integrated Service Network 9, with performance taking place in Lexington, Massachusetts from September 6-7, 2023. As the prime contractor, Takeda Pharmaceuticals America...
- This federal contract award, valued at $32,448.80, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of TAKHZYRO 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a completion date of July 9, 2024. Amerisourcebergen Drug Corp is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Department of Veterans...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order contract to Takeda Pharmaceuticals America Inc., a subsidiary of Takeda Pharmaceutical Company LIMITED, for the supply of LANADELUMAB-FLYO (TAKHZYRO) 15OMG/ML INJ, SYRINGE, 2ML. This contract has a potential value of $110,671.20 and a completion date of June 6, 2024. The contract was issued against Takeda's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule....
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $32,448.80 firm fixed-price delivery order is for the supply of TAKHZYRO 300 MG/2 ML syringes, a specialty medication used for the treatment of hereditary angioedema. The award has an ultimate completion date of May 14, 2024 and was made on April 23, 2024. This delivery order is a part of Amerisourcebergen's...